Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly

被引:24
作者
Cazales, Martine
Boutros, Rose
Brezak, Marie-Christine
Chaumeron, Sophie
Prevost, Gregoire
Ducommun, Bernard
机构
[1] Univ Toulouse 3, CNRS, LBCMCP, UMR 5088,IFR 109, F-31062 Toulouse, France
[2] Inst Henri Beaufour, IPSEN, F-91952 Les Ulis, France
关键词
D O I
10.1158/1535-7163.MCT-06-0299
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The CDC25 cell cycle regulators are promising targets for new pharmacologic approaches in cancer therapy. Inhibitory compounds such as BN82685 have proven to be effective in specifically targeting CDC25 in cultured cells and in inhibiting tumor cell growth. Here, we report that BN82685 impairs microtubule dynamic instability and alters microtubule organization and assembly at the centrosome in interphase cells. Treatment of mitotic cells with BN82685 delays mitotic spindle assembly, chromosome capture, and metaphase plate formation. Furthermore, we show that combining low concentrations of both BN82685 and paclitaxel inhibits the proliferation of HT29 human colon cancer cells. Our results show a role for CDC25 phosphatases in regulating microtubule dynamics throughout the cell cycle and suggest that combinations of CDC25 inhibitors with microtubule-targeting agents may be of therapeutic value.
引用
收藏
页码:318 / 325
页数:8
相关论文
共 29 条
  • [1] G2 and spindle assembly checkpoint adaptation, and tetraploidy arrest: Implications for intrinsic and chemically induced genomic instability
    Andreassen, PR
    Lohez, OD
    Margolis, RL
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2003, 532 (1-2) : 245 - 253
  • [2] The when and wheres of CDC25 phosphatases
    Boutros, R
    Dozier, C
    Ducommun, B
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2006, 18 (02) : 185 - 191
  • [3] Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases
    Brezak, MC
    Quaranta, M
    Contour-Galcera, MO
    Lavergne, O
    Mondesert, O
    Auvray, P
    Kasprzyk, PG
    Prevost, GP
    Ducommun, B
    [J]. MOLECULAR CANCER THERAPEUTICS, 2005, 4 (09) : 1378 - 1387
  • [4] Novel synthetic inhibitor of CDC25 phosphatases:: BN82002
    Brezak, MC
    Quaranta, M
    Mondésert, O
    Galcera, MO
    Lavergne, O
    Alby, F
    Cazales, M
    Baldin, W
    Thurieau, C
    Harnett, J
    Lanco, C
    Kasprzyk, PG
    Prevost, GP
    Ducommun, B
    [J]. CANCER RESEARCH, 2004, 64 (09) : 3320 - 3325
  • [5] Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase
    Brisson, M
    Nguyen, T
    Vogt, A
    Yalowich, J
    Giorgianni, A
    Tobi, D
    Bahar, I
    Stephenson, CRJ
    Wipf, P
    Lazo, JS
    [J]. MOLECULAR PHARMACOLOGY, 2004, 66 (04) : 824 - 833
  • [6] Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression
    Bugler, Beatrix
    Quaranta, Muriel
    Aressy, Bernadette
    Brezak, Marie-Christine
    Prevost, Gregoire
    Ducommun, Bernard
    [J]. MOLECULAR CANCER THERAPEUTICS, 2006, 5 (06) : 1446 - 1451
  • [7] Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis
    Busino, L
    Chiesa, M
    Draetta, GF
    Donzelli, M
    [J]. ONCOGENE, 2004, 23 (11) : 2050 - 2056
  • [8] Cassimeris L, 2001, INT REV CYTOL, V210, P163
  • [9] CDC25B phosphorylation by Aurora-A occurs at the G2/M transition and is inhibited by DNA damage
    Cazales, M
    Schmitt, E
    Montembault, E
    Dozier, C
    Prigent, C
    Ducommun, B
    [J]. CELL CYCLE, 2005, 4 (09) : 1233 - 1238
  • [10] Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M transition
    Dutertre, S
    Cazales, M
    Quaranta, M
    Froment, C
    Trabut, V
    Dozier, C
    Mirey, G
    Bouché, JP
    Theis-Febvre, N
    Schmitt, E
    Monsarrat, B
    Prigent, C
    Ducommun, B
    [J]. JOURNAL OF CELL SCIENCE, 2004, 117 (12) : 2523 - 2531